MedTrace Logo

Effect of Arterio-venous ECMO on Severe Sepsis and ARDS

NCT04555798 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-04-12

No results posted yet for this study

Summary

To evaluate and compare the effect of immunoadsorption effect of A-V ECMO on course of sepsis weaning from inotropes, weaning from the ventilator, duration of ICU stays and effect on mortality rate in patients with septic shock and respiratory failure due to ARDS followed severe lung contusion.

Conditions

  • Patients With Respiratory Failure and Shocked

Interventions

DRUG

Meropenem Injection

patients of both groups given meropenam 1 gram every 8 hours till we collect the sputum culture

DEVICE

A-V ECMO

Only patients of group B connected to A-V ECMO for two weeks

Sponsors & Collaborators

  • King Abdul Aziz Specialist Hospital

    collaborator NETWORK

  • Mohamed Gaber Allam

    lead NETWORK

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-01
Primary Completion
2022-02-01
Completion
2022-02-01
FDA Drug
Yes
FDA Device
Yes

Countries

  • Saudi Arabia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04555798 on ClinicalTrials.gov